Luye Pharma Group (FRA:LUP) Cash And Cash Equivalents : €647.6 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Cash And Cash Equivalents?

Luye Pharma Group's quarterly cash and cash equivalents increased from Dec. 2023 (€415.97 Mil) to Jun. 2024 (€427.66 Mil) and increased from Jun. 2024 (€427.66 Mil) to Dec. 2024 (€647.60 Mil).

Luye Pharma Group's annual cash and cash equivalents increased from Dec. 2022 (€314.65 Mil) to Dec. 2023 (€415.97 Mil) and increased from Dec. 2023 (€415.97 Mil) to Dec. 2024 (€647.60 Mil).

Luye Pharma Group Cash And Cash Equivalents Historical Data

The historical data trend for Luye Pharma Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Cash And Cash Equivalents Chart

Luye Pharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

485.89

338.79

314.65

415.97

647.60

Luye Pharma Group Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															314.65	576.47	415.97	427.66	647.60

Luye Pharma Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Luye Pharma Group (FRA:LUP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Luye Pharma Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (FRA:LUP) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

LYPHF:USA 02186:Hong Kong

Address

Hongqiao Road 1438, 22/F, Gubei International Fortune Center II, Changning District, Shanghai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.

Luye Pharma Group Headlines

No Headlines